{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-323704","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2025-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.438209+00:00","generated_at":"2026-05-16T12:46:03.637762+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Pyxis Oncology MICVO Phase 1 shows 46% ORR monotherapy, 71% ORR with Keytruda in HNSCC","bullets":["MICVO monotherapy at 5.4 mg/kg: 46% confirmed ORR (6/13), 92% DCR in 2L+ R/M HNSCC; no Grade 4/5 TRAEs.","MICVO + Keytruda (3.6/4.4 mg/kg): 71% confirmed ORR (5/7), 100% DCR in 1L/2L+ HNSCC; no TRAE discontinuations.","Sold Enzeshu royalty rights for $11M one-time cash; cash runway extends into Q4 2026.","Monotherapy update expected mid-2026; combo update in 2H26; FDA alignment on pivotal study design obtained."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-323704","json":"https://secwatch.observer/filing/0001193125-25-323704.json","markdown":"https://secwatch.observer/filing/0001193125-25-323704.md","text":"https://secwatch.observer/filing/0001193125-25-323704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000119312525323704/0001193125-25-323704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000119312525323704/pyxs-20251218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:46:03.637762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}